These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1466971)

  • 1. Summary of the Antigenic Variation Working Group.
    Bradac J; Ho D
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1419-21. PubMed ID: 1466971
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV/AIDS research. Potent HIV antibodies spark vaccine hopes.
    Cohen J
    Science; 2009 Sep; 325(5945):1195. PubMed ID: 19729632
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV neutralizing antibodies do not inhibit HIV-induced cell fusion in vitro.
    Emilie D; Delattre RM; Galanaud P; Nicolas JF
    Res Virol; 1991; 142(6):439-42. PubMed ID: 1803411
    [No Abstract]   [Full Text] [Related]  

  • 4. Humoral immunity to the human immunodeficiency virus.
    Weber J
    Curr Opin Immunol; 1989-1990 Feb; 2(3):420-3. PubMed ID: 2483884
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus.
    Wrin T; Crawford L; Sawyer L; Weber P; Sheppard HW; Hanson CV
    J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):211-9. PubMed ID: 8106963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
    Tremblay M; Numazaki K; Li XG; Gornitsky M; Hiscott J; Wainberg MA
    J Immunol; 1990 Nov; 145(9):2896-901. PubMed ID: 1698866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diversity and variation in human immunodeficiency virus: implications for immune control.
    Ramsay AJ
    Immunol Cell Biol; 1992 Jun; 70 ( Pt 3)():215-21. PubMed ID: 1452223
    [No Abstract]   [Full Text] [Related]  

  • 8. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
    Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
    Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human antibodies to HIV-1 by recombinant DNA methods.
    Burton DR; Barbas CF
    Chem Immunol; 1993; 56():112-26. PubMed ID: 8452652
    [No Abstract]   [Full Text] [Related]  

  • 10. [Monoclonal anti-HIV antibodies in HIV/AIDS research. Diagnosis and therapy].
    Giese R; Grunow R
    Allerg Immunol (Leipz); 1989; 35(1):25-37. PubMed ID: 2718887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccines for immunodeficiency viruses.
    Robinson HL
    AIDS; 1997; 11 Suppl A():S109-19. PubMed ID: 9451974
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How does the HIV escape cytotoxic T cell immunity?
    Phillips RE; McMichael AJ
    Chem Immunol; 1993; 56():150-64. PubMed ID: 7680867
    [No Abstract]   [Full Text] [Related]  

  • 14. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
    Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
    Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of a WHO workshop on synthetic peptides in HIV diagnosis and AIDS-related research, Moscow 24-26 May 1989. World Health Organization Global Programme on AIDS.
    AIDS; 1991 Jan; 5(1):WHO1-9. PubMed ID: 1711860
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
    Haynes BF; Moody MA; Verkoczy L; Kelsoe G; Alam SM
    Hum Antibodies; 2005; 14(3-4):59-67. PubMed ID: 16720975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1-O: a variant of HIV-1.
    Commun Dis Rep CDR Wkly; 1994 Jun; 4(24):109. PubMed ID: 7520315
    [No Abstract]   [Full Text] [Related]  

  • 18. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins.
    Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.